AzurRx BioPharma, Inc. (AZRX) News
Filter AZRX News Items
AZRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AZRX News Highlights
- For AZRX, its 30 day story count is now at 18.
- Over the past 29 days, the trend for AZRX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- WAVE, BIO and AFIB are the most mentioned tickers in articles about AZRX.
Latest AZRX News From Around the Web
Below are the latest news stories about AzurRx BioPharma Inc that investors may wish to consider to help them evaluate AZRX as an investment opportunity.
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO DepartsHere''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (NASDAQ: XLRN ) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Corvus Pharmaceuticals, Inc. NASDAQ: CRVS) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) IVERIC bio, Inc. (NASDAQ: ISEE ) Leap Therapeutics, Inc. (NASDAQ: LPTX ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 20) Ambrx Biopharma Inc. (NYSE: AMAM ) Absci Corporation (NASDAQ: ABSI ) Acutus Medical, Inc. (NASDAQ: AFIB ) Aytu Biopharma, Inc. (NASDAQ: AYTU ) AzurRx BioPharma, Inc. (NA... |
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma TodayCompany to begin trading on Nasdaq under new ticker symbol, FBWI, effective September 22 Company to begin trading on Nasdaq under new ticker symbol, FBWI, effective September 22 |
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder StudyHere''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Techne Corporation (NASDAQ: TECH ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Vera Therapeutics, Inc. (NASDAQ: VERA ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) 4D pharma plc (NASDAQ: LBPS ) (announced biomarker analyses from two studies of MRx0518 in solid tumor settings) Achilles Therapeutics plc (NASDAQ: ACH... |
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharmaBOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, regarding its recently announced merger with First Wave Bio, Inc. and adoption of the First Wave BioPharma name. The full text of the letter, which has also been posted to the Company''s website, is as follows: |
36 Stocks Moving In Tuesday's Mid-Day SessionGainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares climbed 25.5% to $6.00. The company on Monday announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractor chronic cough. HC Wainwright on Tuesday raised its price target on the stock. BTCS Inc. (NASDAQ: BTCS) shares climbed 23% to $10.25 as the company commenced trading on The Nasdaq Capital Market. Comm |
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229MAzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma. |
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease IndicationsAzurRx BioPharma to be renamed First Wave BioPharma and trade under new NASDAQ ticker symbol, FWBI |
AzurRx Announces Acquisition Of First Wave Bio, And Creation Of First Wave BioPharma(RTTNews) - AzurRx BioPharma, Inc. (AZRX) has agreed to acquire First Wave Bio, Inc. in a stock and cash deal valued at $229 million. AzurRx will change its corporate name to First Wave BioPharma Inc., and will trade common shares on Nasdaq under ticker symbol, FWBI. First Wave Bio is a clinical-stage biotechnology company specializing in the |
AzurRx BioPharma To Acquire First Wave Bio For $229MAzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments. First Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases (IBD). In conjunction with the acquisition, AzurRx will change its name to First Wave BioPharma and trade on NASDAQ under the new ticker symbol, FWBI, effective by Septemb |
AzurRx BioPharma Announces Reverse Stock SplitCommon Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021 BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-s |